Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 101)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aztreonam |
Approved |
Phase 4 |
|
78110-38-0 |
5362041 5742832 |
Synonyms:
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
78110-38-0
AC1NX3U2
AC-4330
Ambap78110-38-0
Az threonam
Azactam
AZT
Azthreonam
Az-threonam
aztreonam
Aztreonam
Aztréonam
Aztreonam esteve brand
Aztreonam squibb brand
Aztreonamum
BIDD:GT0765
|
BPBio1_000121
BRD-K62607865-001-03-0
Bristol myers squibb brand OF aztreonam
Bristol-myers squibb brand OF aztreonam
BSPBio_000109
CHEBI:161680
CHEMBL158
CID5742832
Esteve brand OF aztreonam
HMS1568F11
HMS2090K09
MolPort-003-886-345
Monobactam
Monobactam, SQ 26776, Squibb 26776, Aztreonam
NCGC00179656-01
NSC646279
Prestwick_914
Prestwick2_000185
Prestwick3_000185
Primbactam
S1505_Selleck
Sanofi winthrop brand OF aztreonam
SQ-26776
Squibb brand OF aztreonam
Urobactam
|
|
2 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
3 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
4 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
5 |
|
Iodine |
Approved, Investigational |
Phase 2, Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
diiodine
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
6 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 498142 38904 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
7 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
8 |
|
Zoledronic Acid |
Approved |
Phase 3 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
ácido zoledrónico
Aclasta
AKOS005145739
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42446
CGP 42'446
CGP 42446A
CGP-42446
CGP-42'446
CHEBI:46557
CHEMBL924
CID68740
|
D08689
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
Novartis brand of zoledronic acid
Novartis brand OF zoledronic acid
NSC721517
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
Zol
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zoledronic acid anhydrous
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
|
|
9 |
|
Prazosin |
Approved |
Phase 3 |
|
19216-56-9 |
4893 |
Synonyms:
[3H]-Prazosin
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
1-(3-Amino-6,7-dimethoxy-2- quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
19216-56-9
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
5-25-13-00365 (Beilstein Handbook Reference)
AB00053528
AC1L1J6T
AKOS000310009
BCBcMAP01_000227
Bio1_000365
Bio1_000854
Bio1_001343
Bio2_000358
Bio2_000838
BPBio1_001006
BRD-K49111258-001-02-8
BRD-K49111258-003-05-7
BRN 0768345
BSPBio_000914
BSPBio_001036
BSPBio_002221
C07368
C19H21N5O4
CAS-19237-84-4
CHEBI:8364
CHEMBL2
CID4893
CP-12299
D08411
DB00457
DivK1c_000375
Douglas brand OF prazosin hydrochloride
EINECS 242-885-8
Furazosin
HCL, Prazosin
HMS1362D17
HMS1792D17
HMS1990D17
HMS2089G09
HSDB 3298
Hydrochloride, prazosin
IDI1_000375
IDI1_002113
Justac
KBio1_000375
KBio2_000376
KBio2_001302
KBio2_002944
KBio2_003870
KBio2_005512
KBio2_006438
KBio3_000731
KBio3_000732
KBio3_001721
KBioGR_000376
KBioGR_000965
|
KBioSS_000376
KBioSS_001302
L000666
Lentopres
LS-140002
Minipress
Minipress (TN)
Minipress Xl
MolPort-000-891-036
NCGC00016740-01
NCGC00016740-02
NCGC00016740-03
NCGC00016740-14
NCGC00024324-02
NCGC00024324-04
NCGC00024324-05
NCGC00024324-06
NCGC00024324-07
NCGC00024324-08
NCGC00024324-09
NCI60_002417
NINDS_000375
Oprea1_314778
Pfizer brand OF prazosin hydrochloride
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI)
Pratsiol
Prazocin
prazosin
Prazosin
Prazosin (INN)
Prazosin [INN:BAN]
Prazosin HCl
Prazosin HCL
Prazosin hydrochloride
Prazosin Hydrochloride
Prazosina
Prazosina [INN-Spanish]
Prazosine
Prazosine [INN-French]
Prazosinum
Prazosinum [INN-Latin]
Prestwick0_000947
Prestwick1_000947
Prestwick2_000947
Prestwick3_000947
SMP1_000063
SPBio_001297
SPBio_003073
Spectrum_000822
Spectrum2_001289
Spectrum3_000551
Spectrum4_000483
Spectrum5_001365
ST075549
STK301545
TL8001573
TNP00312
Tocris-0623
UNII-XM03YJ541D
Vasoflex
ZINC00601304
|
|
10 |
|
Cadexomer iodine |
Experimental |
Phase 2, Phase 3 |
|
94820-09-4 |
|
Synonyms:
|
11 |
|
Hormones |
|
Phase 3 |
|
|
|
12 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
13 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
14 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
15 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
16 |
|
Adrenergic alpha-Antagonists |
|
Phase 3 |
|
|
|
17 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
18 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
19 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
20 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
341031-54-7, 557795-19-4 |
5329102 |
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
|
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
21 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 406563 |
Synonyms:
284461-73-0
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafénib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
22 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
179324-69-7
341, PS
AC1L8TUW
bortezomib
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP 341
LDP341
LDP-341
|
LPD 341
LPD-341
MLN341
MolPort-003-845-298
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
NCI60_029010
NSC681239
NSC-681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
|
|
23 |
|
Calcium carbonate |
Approved, Investigational |
Phase 2 |
|
471-34-1 |
|
Synonyms:
Calcio carbonato
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
Carbonato de calcio
|
Carbonic acid calcium salt (1:1)
Chalk
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
|
|
24 |
|
Vemurafenib |
Approved |
Phase 2 |
|
918504-65-1 |
23252090 42611257 |
Synonyms:
PLX4032
PLX-4032
R05185426
RG7204
RO5185426
|
vemurafenib
Vemurafenib
Vémurafénib
Vemurafenibum
Zelboraf
|
|
25 |
|
Azacitidine |
Approved, Investigational |
Phase 2 |
|
320-67-2 |
9444 |
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AC
5AzaC
5-AZAC
5-azacitidine
5-aza-CR
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5-AZCR
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
cMAP_000082
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
|
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
Ladakamycin
Lopac0_000035
LS-1189
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
mylo sar
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC102816
NSC-102816
Pharmion brand OF azacitidine
Pharmion Brand of Azacitidine
pyrimidine antimetabolite: inhibits nucleic acid replication
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
Spectrum_001262
SPECTRUM1502111
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
ST056940
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
wr 183027
WR-183027
ZINC03861768
|
|
26 |
|
Decitabine |
Approved, Investigational |
Phase 2 |
|
2353-33-5 |
451668 |
Synonyms:
2' Deoxy 5 azacytidine
2353-33-5
2'-Deoxy-5-azacytidine
4-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5 Aza 2' deoxycytidine
5 Azadeoxycytidine
5 Deoxyazacytidine
5A2dc
5-Aza-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-Aza-2'-deoxycytidine
5-aza-CdR
5-aza-dC
5AzadC
5-AzadC
5-AZAdC
5-azadeoxycytidine
5-Azadeoxycytidine
5-Deoxy-2&prime
5-Deoxyazacytidine
A3656_SIGMA
AC-1135
AC1L9PS9
-azacytidine
|
Azadc
AzadC
AzadC compound
CHEBI:50131
CHEMBL1201129
CID451668
Compound, azadc
D03665
DAC
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
DB01262
Decitabina
Decitabine
Decitabine (USAN/INN)
Decitabine mesylate
-Deoxycytidine
Dezocitidine
E-7373
FT-0082622
Mesylate, decitabine
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC127716
NSC-127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
|
|
27 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
28 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
50070211 |
Synonyms:
339177-26-3
ABX-EGF
ABX-EGF MAb
ABX-EGF Monoclonal Antibody
Clone E7.6.3
D05350
panitumumab
|
Panitumumab
Panitumumab (genetical recombination)
Panitumumab (genetical recombination) (JAN)
Panitumumab (USAN/INN)
Vectibix
Vectibix (TN)
|
|
29 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
30 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
Doxo cell
Doxo-cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
31 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
32 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 2 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3Î’,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
31316-19-5
47768_SUPELCO
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
beta-Ol
bmse000510
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
Calciferols
Calciferolum
Calciferon 2
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
component of Geltabs Vitamin D
Condacaps
Condocaps
Condol
Crtron
Crystallina
D00187
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
DB00153
Decaps
Dee-osterol
Dee-Osterol
Dee-ron
Dee-Ron
Dee-ronal
Dee-Ronal
Dee-roual
Dee-Roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
D-Tracetten
E5750_SIGMA
EINECS 200-014-9
Ercalciol
ergocalciferol
|
Ergocalciferol
Ergocalciférol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
'Ergosterol irradiated'
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
Haliver
Hi-deratol
Hi-Deratol
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
Metadee
Mina D2
MLS001332467
MLS001332468
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
Novovitamin-D
NSC 62792
NSC62792
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick_554
Prestwick3_000420
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
Shock-ferol
Shock-ferol sterogyl
SMR000857106
Sorex C.R
Sorex C.R.
SPECTRUM1500276
Spectrum5_000666
ST057150
Sterogyl
STOCK1N-53397
Synthetic vitamin D
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
Viosterol in Oil
Vitamin D 2
vitamin d-2
Vitamin D2
Vitamin- D2
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
Vitamin-?D2
VITAMIN_D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
|
|
33 |
|
Alfacalcidol |
Approved, Nutraceutical |
Phase 2 |
|
41294-56-8 |
5282181 |
Synonyms:
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1a,3b-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1a-Hydroxyvitamin D3 / 1a-hydroxycholecalciferol
1alpha-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-hydroxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
1α-hydroxycholecalciferol
|
1Α-hydroxycholecalciferol
1α-hydroxyvitamin D3
1α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3
1Α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
34 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
35 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
60-18-4 |
6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
(S)-Α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
36 |
|
Tremelimumab |
Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
|
Ticilimumab
tremelimumab
Tremelimumab
|
|
37 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
39 |
|
Nutrients |
|
Phase 2 |
|
|
|
40 |
|
Micronutrients |
|
Phase 2 |
|
|
|
41 |
|
Vitamin D2 |
|
Phase 2 |
|
|
|
42 |
|
Antacids |
|
Phase 2 |
|
|
|
43 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
44 |
|
Ergocalciferols |
|
Phase 2 |
|
|
|
45 |
|
Vitamins |
|
Phase 2 |
|
|
|
46 |
|
Trace Elements |
|
Phase 2 |
|
|
|
47 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
48 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
49 |
|
Calciferol |
|
Phase 2 |
|
|
|
50 |
|
Hydroxycholecalciferols |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 123)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent |
Unknown status |
NCT01057563 |
Phase 4 |
|
2 |
A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. |
Terminated |
NCT03158116 |
Phase 4 |
Inhaled Aztreonam |
3 |
Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. |
Completed |
NCT00295763 |
Phase 3 |
Thyrogen (thyrotropin alfa for injection) |
4 |
Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) |
Completed |
NCT01083550 |
Phase 2, Phase 3 |
|
5 |
Pediatric Asthma Controller Trial (PACT) |
Completed |
NCT00272506 |
Phase 3 |
inhaled corticosteroid;long-acting beta2-agonist |
6 |
Non-small Cell Lung Cancer Study US75 (Z-PACT) |
Completed |
NCT00086268 |
Phase 3 |
zoledronic acid;Taxotere;Carboplatin |
7 |
CSP #563 - Prazosin and Combat Trauma PTSD (PACT) |
Completed |
NCT00532493 |
Phase 3 |
prazosin |
8 |
Models of Primary Osteoporosis Screening in Male Veterans |
Active, not recruiting |
NCT04079868 |
Phase 2, Phase 3 |
|
9 |
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer |
Completed |
NCT00668811 |
Phase 2 |
SU011248, Sutent |
10 |
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements |
Completed |
NCT00559949 |
Phase 2 |
Selumetinib |
11 |
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma |
Completed |
NCT00887107 |
Phase 2 |
Sorafenib (nexavar) |
12 |
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma |
Completed |
NCT00104871 |
Phase 2 |
Bortezomib |
13 |
Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients |
Completed |
NCT00630214 |
Phase 2 |
|
14 |
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma |
Completed |
NCT01502410 |
Phase 2 |
sorafenib tosylate |
15 |
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer |
Completed |
NCT02138214 |
Phase 2 |
|
16 |
Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer |
Completed |
NCT02408887 |
Phase 2 |
|
17 |
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine |
Completed |
NCT01286753 |
Phase 2 |
Vemurafenib |
18 |
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine |
Completed |
NCT00085293 |
Phase 2 |
Decitabine |
19 |
The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. |
Completed |
NCT00207493 |
Phase 1, Phase 2 |
|
20 |
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial |
Recruiting |
NCT03753919 |
Phase 2 |
Durvalumab;Tremelimumab |
21 |
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy |
Recruiting |
NCT02593175 |
Phase 2 |
Carboplatin;Paclitaxel |
22 |
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer |
Recruiting |
NCT02876107 |
Phase 2 |
Carboplatin;Paclitaxel |
23 |
Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study |
Unknown status |
NCT00103155 |
Phase 1 |
|
24 |
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors |
Completed |
NCT01100619 |
Phase 1 |
rosiglitazone;XL184 |
25 |
Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and |
Completed |
NCT03470259 |
Phase 1 |
IV adminstration of EMI-137 |
26 |
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients |
Recruiting |
NCT03469011 |
Phase 1 |
Imatinib Oral Tablet |
27 |
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) |
Active, not recruiting |
NCT02791334 |
Phase 1 |
LY3300054;Ramucirumab;Abemaciclib;Merestinib;LY3321367 |
28 |
Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma |
Not yet recruiting |
NCT04389281 |
Phase 1 |
|
29 |
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma |
Unknown status |
NCT01417442 |
Early Phase 1 |
|
30 |
99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study |
Unknown status |
NCT00984191 |
|
|
31 |
Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial |
Unknown status |
NCT02140476 |
|
|
32 |
Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE® Scalpel and LigaSure Preciseâ„¢ Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial |
Unknown status |
NCT01565486 |
|
|
33 |
Differences Protein Expression in Papillary Thyroid Carcinoma |
Unknown status |
NCT02814032 |
|
|
34 |
Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma |
Unknown status |
NCT02648399 |
|
|
35 |
Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound |
Unknown status |
NCT00929318 |
|
|
36 |
Effectiveness and Cost-effectiveness of Interdisciplinary Teamwork in Medical Emergencies: The PAtient-Centred Team (PACT) Service Model. Effect and Cost Effectiveness Evaluation |
Unknown status |
NCT02541474 |
|
|
37 |
Peer-lead and Telemedicine Activated Care (PACT) in Diabetes Prevention and Management |
Unknown status |
NCT01307137 |
|
|
38 |
The PACT Trial - PAtient Centered Telerehabilitation: Effectiveness of Software-supported and Traditional Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation: Design of a Randomized Controlled Trial. |
Unknown status |
NCT02076490 |
|
|
39 |
Falls Prevention Through Physical And Cognitive Training (Falls PACT) in Older Adults With Mild Cognitive Impairment: A Randomised Controlled Trial |
Unknown status |
NCT03167840 |
|
|
40 |
Prophylactic Central Neck Dissection for Papillary Thyroid Cancer |
Completed |
NCT01510002 |
|
|
41 |
Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules |
Completed |
NCT04594720 |
|
|
42 |
Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study |
Completed |
NCT01927887 |
|
Ferumoxytol |
43 |
Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer |
Completed |
NCT03363347 |
|
Redifferentiation with retinoid acid |
44 |
Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy |
Completed |
NCT02768753 |
|
|
45 |
Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy |
Completed |
NCT01354639 |
|
|
46 |
Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC |
Completed |
NCT02561533 |
|
|
47 |
A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction |
Completed |
NCT01311089 |
|
|
48 |
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 |
Completed |
NCT01534897 |
|
GSK2118436 |
49 |
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. |
Completed |
NCT02323724 |
|
|
50 |
The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis |
Completed |
NCT01103557 |
|
|
|